Lantern Pharma to Host Webcast on Fourth Quarter and Fiscal Year 2025 Results

Lantern Pharma (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2025 operating and financial results on March 30 at 4:30 p.m. Eastern Time. Management, led by President and Chief Executive Officer Panna Sharma, will review results for the period ended Dec. 31, 2025 and provide updates on upcoming milestones, clinical trials and developments related to its RADR (R) AI and machine learning platform. The company is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR (R) platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development timelines, and improve patient outcomes.

The announcement matters because it represents a critical opportunity for stakeholders to assess Lantern Pharma's financial health and operational progress in a sector where artificial intelligence is increasingly becoming a transformative force. The webcast will provide insights into how the company's RADR platform is performing in real-world applications, particularly in the high-stakes field of oncology drug development. Investors and industry observers will be watching closely for updates on clinical trials and milestones that could validate the company's AI-driven approach to drug discovery.

This event is important as it comes at a time when biotechnology companies are under pressure to demonstrate both financial sustainability and technological innovation. Lantern Pharma's focus on using artificial intelligence to streamline drug development processes addresses two key challenges in the pharmaceutical industry: reducing development costs and shortening timelines from discovery to market. The implications of this announcement extend beyond quarterly financials, potentially signaling broader trends in how AI is being integrated into life sciences research and development.

The webcast will be accessible to the public, with the latest news and updates relating to LTRN available in the company's newsroom at https://ibn.fm/LTRN. This transparency allows for broader market participation and understanding of the company's strategic direction. The event's timing and content will likely influence investor perception of Lantern Pharma's ability to execute its business model and maintain competitive advantage in the rapidly evolving AI-driven biotechnology landscape.

AINewsWire, the specialized communications platform that distributed this announcement, focuses on the latest advancements in artificial intelligence, including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio that delivers various communication solutions, including access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. More information about AINewsWire is available at https://www.AINewsWire.com, with full terms of use and disclaimers applicable to all content provided by AINW available at https://www.AINewsWire.com/Disclaimer.